Leukemia Research
Volume 34, Issue 10 , Pages 1325-1329 , October 2010

Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells

  • Xiaofang Wang

      Affiliations

    • Department of Hematology, Cancer Hospital of Tianjin, Tianjin Medical University, Key Laboratory of Cancer Prevention and Therapy, Ti-Yuan-Bei, Huan-Hu-Xi-Road, Tianjin 300060, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 22 23341552; fax: +86 22 23359904.
    • ,
  • Zhiqing Zhang

      Affiliations

    • Department of Neurology, Dalian Central Hospital, Dalian, PR China
    • ,
  • Cheng Yao

      Affiliations

    • Department of Hematology, The First Hospital, Jilin University, Changchun, PR China

Received 17 November 2009 ,Revised 9 May 2010 ,Accepted 11 May 2010.

References 

  1. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247:1457–1460
  2. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–1165
  3. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001;98:1897–1903
  4. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult mesenchymal stem cells. Science. 1999;284:143–147
  5. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74
  6. Silva WA, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells. 2003;21:661–669
  7. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24:986–991
  8. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In Vitro Cell Dev Biol—Anim. 2008;44:169–177
  9. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175–1182
  10. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713–1724
  11. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182
  12. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognostic marker in non-small cell lung cancers. J Clin Oncol. 1999;17:2100–2104
  13. Kawasaki H, Altieri DC, Lu C-D, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1999;58:5071–5074
  14. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell. 1998;11:115–124
  15. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79:1121–1126

PII: S0145-2126(10)00250-X

doi: 10.1016/j.leukres.2010.05.006

Leukemia Research
Volume 34, Issue 10 , Pages 1325-1329 , October 2010

Article Tools

* Image Usage & Resolution